As it transitions from a discovery- to a clinical-stage biotech, Volastra Therapeutics is bringing longtime adviser Samuel ...

Johnson & Johnson is jettisoning several programs, with three of the culls taking place in the neuroscience field. | Johnson ...

Sanofi is putting down $18 million across three historically Black medical schools as part of the French pharma's efforts to boost clinical trial diversity.   | Big Pharma Sanofi is putting down $18 ...

Johnson & Johnson has burnished the evidence for nipocalimab, adding a sliver of data in adolescents with generalized ...

Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...

TORONTO—While the FDA has already doled out green lights to about 950 medical devices backed by artificial intelligence or ...

Amid a reorganization campaign that’s breathed new life into hybrid generic and innovative medicines player Teva, the company ...

Cell therapy biotech Tolerance Bio has unveiled with $17.2 million and a mission of targeting immune diseases by stretching ...

Ocean Biomedical has signed a $32 million biobucks deal with a Polish biotech to secure the rights to a batch of preclinical ...

Ceribell rang in a $180.3 million IPO last week, with its public debut on the Nasdaq coming in well above its first pricing ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

Eli Lilly is expanding its innovation digs to Beijing, China, opening two research centers called the Eli Lilly China Medical Innovation Center and Lilly Gateway Labs.  | Eli Lilly is expanding its ...